Weekly pill could cut migraine days in half

NCT ID NCT07072910

Recruiting now Disease control Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a weekly dose of cabergoline, a drug that affects dopamine, can reduce the number of migraine days in adults with episodic migraine (4-14 migraine days per month). 150 participants will be randomly assigned to receive cabergoline (0.5 mg or 1.0 mg) or a placebo once a week for 12 weeks, followed by an open-label phase where everyone gets cabergoline. The study tracks migraine frequency, severity, and medication use through daily diaries and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabergoline (Dostinex), a dopamine receptor agonist taken as a weekly oral tablet
What this could lead to: If it works, this could provide a new, once-weekly preventive option for people with episodic migraine, reducing the number of migraine days per month.
What could go wrong: This is an early phase 2 trial with only 150 participants, so results may not apply to everyone. Cabergoline can cause side effects like nausea, dizziness, or heart valve issues, and it may not prove more effective than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Aarhus University Hospital
RECRUITING

Aarhus N, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.